Reversible inhibition of type B monoamine oxidase. Theoretical study of model diazo heterocylic compounds

Author： Wouters J. Ooms F. Jegham S. Koenig J. George P. Durant F.

Publisher： Elsevier

ISSN： 0223-5234

Source： European Journal of Medicinal Chemistry, Vol.32, Iss.9, 1997-09, pp. : 721-730

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Evaluation of monoamine oxidase B inhibition by fluoxetine (Prozac): An in vitro and in vivo study

By Mukherjee J. Yang Z.-Y.

European Journal of Pharmacology, Vol. 337, Iss. 1, 1997-10 ,pp. : 111-114

Elsevier

Access to resources Recommend Favorite

Monoamine Oxidase-B Inhibition in Alzheimer's Disease

By Riederer P. Danielczyk W. Grunblatt E.

Neurotoxicology, Vol. 25, Iss. 1, 2004-01 ,pp. : 271-277

Elsevier

Access to resources Recommend Favorite

Leflunomide, a Reversible Monoamine Oxidase Inhibitor

Central Nervous System Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Central Nervous System Agents), Vol. 16, Iss. 2, 2016-08 ,pp. : 112-119

Bentham Science Publishers

Access to resources Recommend Favorite

Monoamine oxidase A and B inhibitors

By Jegham S. George P.

Expert Opinion on Therapeutic Patents, Vol. 8, Iss. 9, 1998-09 ,pp. : 1143-1150

Informa Healthcare

Access to resources Recommend Favorite

The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy

By Elmer Lawrence W Bertoni John M

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 16, 2008-11 ,pp. : 2759-2772

Informa Healthcare

Access to resources Recommend Favorite